Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • AYUSH
    • ICRA upgrades long...

    ICRA upgrades long term rating on Patanjali Ayurved

    Written by supriya kashyap kashyap Published On 2017-01-21T12:30:15+05:30  |  Updated On 21 Jan 2017 12:30 PM IST
    ICRA upgrades long term rating on Patanjali Ayurved

    New Delhi : Credit rating agency ICRA has upgraded long term rating on Baba Ramdev-led Patanjali Ayurved Ltd (PAL) to enhanced degree of adequate safety with stable outlook citing the company's "robust revenue growth in FY 2016" and increased brand penetration.


    "ICRA has upgraded the long term rating of Patanjali Ayurved Ltd from A minus to A plus for Rs 300-crore fund based facilities. The outlook on the long-term rating is Stable," ICRA said.


    It further said: "ICRA has also upgraded the short term rating of PAL from A two plus to A one for Rs 20 crore non fund based facilities."


    Explaining the rationale of the rating upgrade, ICRA said it factored in PAL's robust revenue growth in FY2016 (Rs 4,812 crore from Rs 2,007 crore in FY2015) and the current fiscal (around Rs 3,600 crore in seven months), supported by increasing brand penetration through strengthened marketing in the recent past and strong following of Baba Ramdev among others.


    Moreover, with continuous new product introduction, the Haridwar-based company has "one of the widest product portfolio amongst the FMCG players operating in India."


    PAL has also strengthened its distribution network by adding both number as well as layers of intermediaries in order to support the business growth.


    "These factors combined with partial backward integration and relatively lower selling and administrative overheads have enabled PAL to maintain its healthy profitability margins and return indicators, in spite of high competitive pressures," it said.


    ICRA further added: "PAL's liquidity remains strong on the back of healthy internal accrual generation, sizeable cash balances and limited debt repayment liability resulting in moderate utilisation of the working capital limits availed from the bank. This coupled with a sizeable net worth has continued to result in low gearing levels and robust debt protection metrics."

    AyurvedaBaba RamdevFMCGICRAPatanjaliPatanjali Ayurved
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok